Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

•IPASS: open-label study of first-line gefitinib vs carboplatin/paclitaxel in NSCLC.•IPASS confirmed that EGFR mutation status predicted response to EGFR TKIs.•Blind independent central review of IPASS outcomes was conducted (FDA request).•Review of IPASS outcomes supported findings of the original investigators.•EGFR TKI therapy is thus verified as standard-of-care in this first-line setting..